NEWS
Our newsfeed for conventions, publications and general news adressing the research of pain & medication
FULL SERVICE STUDY CONDUCT
We offer
High validity
Economically run and time-saving trials, by using computer-assisted, online procedures while acquiring sample sizes in between n=16 to 30 participants of our pool of trial-participants.
Our trials are ethics compatible intra-individual crossover designs, in which each participant is his/her own control condition, resulting in a low variability for a complex and efficient repeated measurement statistic with baseline adjustment.
TEAM
PUBLICATIONS
INNOVATIONS
projects completed
25
years of experience
0
Experience matters
For your research you need the best in terms of expertise with HPR
Recent Posts
- HPR’s research on topical compound by Alzecure Pharma – presented June 9-11 and June 16-18 at IASP 2021 World Congress on Pain May 18, 2021
- Invited Speech at NIH Pain Workshop Washington DC Nov 15th 2018 (Video Cast) November 22, 2018
- Important invitation by NIH to participate in “Discovery of Biomarkers to Develop Transformational Non-Addictive Therapeutics for Pain” August 8, 2018
- A Phase I, randomized, double-blind, laser evoked potential study to evaluate the analgesic/anti-hyperalgesic effect of ASP9226, a state-dependent N-type voltage-gated calcium channel inhibitor, in healthy male subjects December 20, 2017
- A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects December 20, 2017
- Investigation of the predictive validity of laser- EPs in normal, UVB-inflamed and capsaicin-irritated skin with four analgesic compounds in healthy volunteers December 20, 2017
- HPR Poster Präsentation und Konferenzteilnahme am 15. IASP Schmerzkongress in Buenos Aires 2014 June 30, 2014
- HPR Poster Presentation at the 15th World Congress on Pain in Buenos Aires 2014 June 30, 2014
- HPR Dr. Schaffler GmbH führt klinische Studie Phase 1B an Z944 in Zusammenarbeit mit Zalicus durch… June 30, 2014
- HPR Dr. Schaffler GmbH in cooperation with Zalicus announces positive results of Z944 Phase 1B Clinical Study in Pain June 30, 2014